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PURPOSE. Multiple genes have been associated with primary open angle glaucoma (POAG) in
Caucasian populations. We now examine the association of these loci in populations of
African ancestry, populations at particularly high risk for POAG.
METHODS. We genotyped DNA samples from two populations: African American (1150 cases
and 999 controls) and those from Ghana, West Africa (483 cases and 593 controls). Our
analysis included 57 single nucleotide polymorphisms (SNPs) in five loci previously associated
with POAG at the genome-wide level, including CDKN2B-AS1, TMCO1, CAV1/CAV2,
chromosome 8q22 intergenic region, and SIX1/SIX6. We evaluated association in the full
datasets, as well as subgroups with normal pressure glaucoma (NPG, maximum IOP 21 mm
Hg) and high pressure glaucoma (HPG, IOP >21 mm Hg).
RESULTS. In African Americans, we identified an association of rs10120688 in the CDNK2B-AS1
region with POAG (P ¼ 0.0020). Several other SNPs were nominally associated, but did not
survive correction for multiple testing. In the subgroup analyses, significant associations were
identified for rs10965245 (P ¼ 0.0005) in the CDKN2B-AS1 region with HPG and rs11849906
in the SIX1/SIX6 region with NPG (P ¼ 0.006). No significant association was identified with
any loci in the Ghanaian samples.
CONCLUSIONS. POAG genetic susceptibility alleles associated in Caucasians appear to play a
greatly reduced role in populations of African ancestry. Thus, the major genetic components
of POAG of African origin remain to be identified. This finding underscores the critical need to
pursue large-scale genome-wide association studies in this understudied, yet disproportion-
ately affected population.
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Glaucoma is the second-leading cause of blindness in theworld.1 Primary open angle glaucoma (POAG) is the most
common type and is inherited as a complex trait.2–4 POAG is
characterized by progressive retinal ganglion cell death, optic
nerve head excavation, and visual field loss. POAG dispropor-
tionately affects individuals of African ancestry,5,6 and is the
most common cause of permanent blindness in African
Americans.7 The risk of POAG in persons older than 40 is 4-
to 5-fold higher in African Americans (4%–5%) than in age-
matched Caucasians (1%).5,8–10 It is also more severe, with a 10-
fold higher risk of blindness from glaucoma in African
Americans.1,11 POAG is even more common and severe in
continental African populations.12–16 In a major population-
based study in Ghana, West Africa, POAG was diagnosed in 6%
of those older than 40, which is one of the highest global
prevalence rates ever reported.14 In studies conducted in eye
clinics serving populations of African ancestry, rates of
blindness in one or both eyes have been observed in excess
of 40%.13,17–20
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Genetics has been shown to play an important role in the
pathogenesis of POAG.2–4,21,22 Previous linkage-based studies
have identified several genes with varying contribution to
glaucoma, including myocilin, CYP1B1, optineurin, and
WDR36.23–26 It has also been reported that DNA copy number
changes in TBK1 and GALC gene contribute to POAG
pathogenesis.27,28 Recently, genome-wide association studies
(GWAS) of POAG in Iceland, Australia, Japan, and the United
States have successfully identified and confirmed genetic
associations that are significant at the genome-wide level with
multiple genes involved in the pathogenesis of POAG,
including CAV1/CAV2, CDKN2B-AS1, TMCO1, SIX1/SIX6,
and an intergenic region on chromosome 8q22.29–32 Multiple
studies have confirmed or replicated these genetic associations
in populations from Europe, the United States, Japan, and
Barbados.33–36 However, these loci have not been examined in
populations of African ancestry, including African Americans
and continental Africans. This study was designed to fill this
significant gap.
We have assembled the International Consortium of African
Ancestry REsearch in Glaucoma (ICAARE-Glaucoma) with
glaucoma investigators from the United States and Africa
(including Ghana, Nigeria, and South Africa). In this study, we
used a haplotype-tagging approach to examine genetic
associations in more than 3200 African American and Ghanaian
(West African) glaucoma cases and controls from the ICAARE-
Glaucoma.
MATERIALS AND METHODS
Study Sample and Phenotype Description
This study adhered to the tenets of the Declaration of
Helsinki. Written informed consent was obtained from all
participating individuals. The research was reviewed and
approved by the institutional review board from all
participating institutions, including Duke University Medical
Center (Durham, NC), the Massachusetts Eye and Ear
Infirmary (Boston, MA), the University of Michigan (Ann
Arbor, MI), New York Eye and Ear Infirmary (New York, NY),
the University of Alabama at Birmingham (Birmingham, AL),
and, for Ghanaian subjects, Noguchi Memorial Institute of
Medical Research of the College of Health Sciences,
University of Ghana in Accra.
Subjects with POAG were unrelated and met the
following inclusion criteria37: glaucomatous optic neuropa-
thy in at least one eye, and visual field loss consistent with
optic nerve damage in at least one eye. Glaucomatous optic
neuropathy was defined as a cup-to-disc ratio greater than
0.7 or focal loss of the nerve fiber layer resulting in a notch
in the neuroretinal rim, associated with a glaucomatous
visual field defect. Visual fields were performed using
standard automated perimetry or frequency doubling test
(FDT).1 IOP was recorded but not used as an inclusion
criterion. The exclusion criteria for POAG subjects included
the diagnosis or history of any secondary glaucoma, history
of ocular trauma, or significant use of systemic or ocular
glucocorticoids. Medical records for all POAG cases and
control subjects were reviewed by professionally trained
glaucoma specialists. The examined control subjects were
unrelated and met the following criteria: no known first-
degree relative with glaucoma, IOP less than 21 mm Hg in
both eyes without treatment, and no evidence of glaucoma-
tous optic neuropathy in either eye. POAG cases were
further stratified into high-pressure glaucoma (HPG) or
normal-pressure glaucoma (NPG) based on maximum re-
corded IOP higher than 21 mm Hg or lower than 22 mm Hg,
respectively.
DNA Genotyping and Association Analysis
Genomic DNA was extracted from peripheral blood by
standard techniques (Gentra, Minneapolis, MN). HaploView
version 4.2 (Broad Institute, Cambridge, MA) was used to
design the tagging single nucleotide polymorphism (SNPs) of
CAV1/CAV2, CDKN2B-AS1, TMCO1, and SIX1/SIX6 in
African (YRI) samples, using genotype data from the HapMap
project (www.hapmap.org) with r2 greater than 0.6 and
minor allele frequency (MAF) greater than 0.05.14 A total of
50 tagging SNPs were selected to cover the linkage
disequilibrium (LD) blocks of the selected candidate regions
(Supplementary Fig. S1). We also included seven additional
SNPs (rs284489 on chromosome 8; rs1063192, rs4977756,
rs10116277, and rs4977574 in the CDKN2B-AS1 region; and
rs33912345 and rs10483727 in the SIX1/SIX6 region) that
were strongly associated with POAG in Caucasians.32,38
TaqMan allelic discrimination assays were employed for
genotyping these 57 SNPs by use of Assays-On-Demand
products with the ViiA7 Realtime PCR system with 384-well
block according to the standard protocols from the manu-
facturer (Applied Biosystems, Foster City, CA). All 57 SNPs
were genotyped in 1076 Ghanaians. Due to technical issues,
50 SNPs were genotyped on the whole set of 2149 African
Americans. Seven SNPs (rs10800149 and rs7518099 in
TMCO1 region; rs2151280, rs1547705, rs10738607, and
rs10811658 in CDKN2B-AS1 region; and rs3759688 in
SIX1/SIX6 region) were genotyped in 1593 African Ameri-
cans. For quality control (QC) purposes, two CEPH (the
Centre d’Etude du Polymorphisme Humain, Foundation Jean
Dausset, Paris, France) standards were included in each 96-
well plate, and samples from two individuals were duplicated
across all plates, with the laboratory technicians masked to
their identities. Analysis of genotypes required matching QC
genotypes within and across plates and at least 95%
genotyping efficiency.
Analysis of Hardy-Weinberg equilibrium (HWE) was
performed separately for cases and controls from the two
populations using GDA software (University of Connecticut,
Storrs, CT).15 Within each population, genotype frequencies
of POAG cases and controls were compared by logistic
regression with adjustment for age and sex using SAS
software (SAS Institute, Inc., Cary, NC). SNP genotypes
were coded according to a log-additive model, in which the
relative risk for carriers of two variant (minor) alleles,
compared to the reference group (homozygous wild type),
was assumed to be the square of the relative risk for carriers
of one variant. We also performed the association analysis
based on classification of NPG or HPG. To correct for testing
multiple SNPs in each genomic region, we calculated the
effective number of independent marker loci (MeffLi) to
control the experiment-wise level of significance and the
false discovery rate based on the method reported by Li and
Ji.39 The values of MeffLi are 6.000 for TMCO, 9.106 for
CAV1/CAV2, 19.146 for CDKN2B-AS, and 7.000 for SIX1/
SIX6. The experiment-wide significance threshold required
to limit type 1 error rate to 5% is 0.0085 for TMCO, 0.0056
for CAV1/CAV2, 0.0027 for CDKN2B-AS1, and 0.0073 for
SIX1/SIX6. Because there is only one SNP in the chromo-
some 8 locus, the significance for P value cutoff is 0.05.
Power calculations were performed with QUANTO software
(University of Southern California, Los Angeles, CA) using
previously described methods, assuming a population
prevalence of 5% and a log-additive risk model.37,40 To
address the genetic heterogeneity between the African
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American and Ghanaian populations, we conducted a formal
meta-analysis of the SNPs with the African American and
Ghanaian datasets with PLINK (Massachusetts General
Hospital, Boston, MA).41
RESULTS
The ICAARE-Glaucoma dataset at the time of this study
consisted of 2149 African Americans and 1076 Ghanaians
(West African). The African American cohort contained 1150
POAG cases and 999 fully ophthalmically examined controls.
The Ghanaian cohort contained 483 POAG cases and 593
examined controls. Phenotypic information is provided in
Table 1. Although elevated IOP was not required for the
diagnosis of POAG, the Ghanaian POAG cases essentially all
demonstrated elevated IOP at examination so NPG subset
analysis was not performed.
All SNPs passed rigorous quality control and genotyping
efficiency criteria (>95% with all the samples). All were in
HWE in both cases and controls from both African Americans
and Ghanaians (P > 0.01), except for two SNPs with minor
deviations (rs1063192 in African American controls [HWE P¼
0.007], rs4977574 in African American cases [HWE P ¼
0.003]). SNP rs1063192 in the CDKN2B-AS1 region was
monomorphic in Ghanaian controls and rare in Ghanaian
POAG cases (a minor allele frequency of 0.002 for the C allele
that is protective in the Caucasian POAG.)
In the full African American case/control dataset, we
observed a significant association of SNP rs10120688 in the
CDKN2B-AS1 region with POAG risk (P ¼ 0.0020; odds ratio
[OR] 1.21, 95% confidence interval [CI] 1.07–1.37). Several
other SNPs reached nominal significance (P < 0.05), including
rs7518099 in the TMCO1 region; rs1052990 and rs4236601 in
the CAV1/CAV2 region; and rs7049105, rs16905597,
rs16905599, rs10811658, and rs10965245 in the CDKN2B-
AS1 region (Table 2). However, these associations did not
survive correction for multiple testing. In the Ghanaian
population, nominal associations were noted for several SNPs,
including rs3807986, rs3815412, and rs8713 in the CAV1/
CAV2 region. However, none of these associations remained
significant after correction for multiple testing in each genomic
region. The meta-analysis with these two populations identified
five nominally significant SNPs (P < 0.05), including rs7518099
and rs2814471 in TMCO1, rs4236601 in CAV1/CAV2, and
rs10120688 and rs16905597 in CDKN2B-AS1, that did not
survive correction for multiple testing.
Next, we stratified the African American cases by IOP
history into NPG and HPG for association analysis using logistic
regression. In the HPG subgroup, we identified significant
association with SNP rs10965245 (P¼0.0005; OR 0.73, 95% CI
0.61–0.87) in the CDKN2B-AS1 region. Nominal associations
that did not survive correction for multiple testing were noted
for several SNPs, including rs4236601 in the CAV1/CAV2
region, and rs7049105, rs10120688, rs16905597, rs16905599,
rs10965235, and rs17761446 in the CDKN2B-AS1 region
(Table 2).
In the NPG subgroup, we found significant association with
SNP rs11849906 in the SIX1/SIX6 regions (P¼0.006; OR 0.53,
95% CI 0.34–0.83). Nominal associations that did not survive
correction for multiple testing were observed with several
SNPs, including rs7518099 and rs2814471 in the TMCO1
region, rs4236601 in the CAV1/CAV2 region, and rs10120688
and rs4977756 in the CDKN2B-AS1 region (Table 2). Addition-
al details of the association with all 57 SNPs in these five
genomic regions are presented in Supplementary Table S1. The
Ghanaian POAG cases were almost all classified as HPG, so
stratification by IOP was not performed.
To determine the statistical power of these datasets to
detect association with these genetic loci, we selected an OR
of 1.50 and 1.35 obtained from reports on the genetic
associations in these regions. Reported ORs were 1.68 for
TMCO1,32 1.4 to 1.5 for CDKN2B-AS1,29,32 1.32 for SIX1/
SIX6,29,35 and 1.36 for CAV1/CAV2 variants.33,42 Statistical
power to detect association with these genomic loci was
calculated using QUANTO software.40 Assuming population
risk a¼0.05 and allele frequency of 0.10, our African American
dataset has 98.9% power for OR of 1.50 and 87.2% power for
OR of 1.35. The Ghanaian dataset has 85% power for OR of
1.50 and 59% power for OR of 1.35. In summary, our African
American and Ghanaian datasets were well powered to detect
associations in these regions.
DISCUSSION
Our study represents the largest association study of glaucoma
to date in populations of African ancestry. We replicated the
association of POAG with the CDKN2B-AS1 locus in the
African Americans first reported in populations of European
ancestry.6,29,32,34,35,43,44 After stratification for IOP, this associ-
ation remained significant in the HPG subgroup. We also found
significant association of the SIX1/SIX6 locus in African
American cases in the NPG subgroup. Interestingly, we did
not observe significant association with any of the previously
reported genes and loci in POAG cases from the West African
population of Ghana. This may be due to the relatively limited
sample size of the Ghanaian dataset.
Several studies have reported the association of CDKN2B-
AS1 SNPs, and on stratification by IOP history, this association
is restricted to the NPG but not the HPG subpopula-
tion.29,32,38,43–46 In African Americans, we see significant
association with CDKN2B-AS1 SNPs in the full dataset and in
the HPG subgroup. This difference in pattern may be due to
TABLE 1. Clinical Characteristics of Individuals in ICAARE-Glaucoma
Affection Status n % Female Age, y Maximal IOP, mm Hg
African American total 2149 51.9 58.1 6 13.4 22.2 6 9.0
African American cases 1150 49.5 57.0 6 13.0 26.2 6 8.8
African American HPG 870 48.7 56.0 6 12.7 30.0 6 7.4
African American NPG 280 49.8 58.9 6 13.3 16.9 6 3.6
African American Controls 999 54.6 59.4 6 13.8 15.2 6 3.1
Ghanaians total 1076 51.3 63.3 6 11.8 31.2 6 12.6
Ghanaian cases 483 43.9 63.4 6 12.4 35.1 6 11.6
Ghanaian controls 593 57.3 63.3 6 9.6 18.4 6 5.6
Age, age at diagnosis for cases and age of examination for controls.
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TABLE 2. The Genetic Association of 57 SNPs With POAG in the ICAARE-Glaucoma Samples of African Americans and Ghanaians (West Africans)
Using Logistic Regression With Additive Model
Genomic
Region SNP Allele
AA, n ¼ 1150
Case/999 Control
AA HPG, n ¼ 870
Case/999 Control
AA NPG, n ¼ 280
Case/999 Control
Ghanaian, n ¼ 483
Case/593 Control
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
TMCO1 rs10800149 A 0.66 1.04 (0.89–1.21) 0.74 0.97 (0.82–1.15) 0.09 1.21 (0.97–1.51) 0.10 1.19 (0.97–1.46)
TMCO1 rs10800150 C 0.49 0.96 (0.85–1.08) 0.74 0.98 (0.86–1.11) 0.29 0.90 (0.75–1.09) 0.24 0.90 (0.76–1.07)
TMCO1 rs4656461 C 0.74 1.02 (0.89–1.18) 0.82 1.02 (0.87–1.19) 0.62 1.06 (0.85–1.32) 0.19 1.14 (0.94–1.40)
TMCO1 rs1913845 C 0.74 1.03 (0.88–1.20) 0.40 1.08 (0.91–1.27) 0.31 0.89 (0.71–1.12) 0.76 0.97 (0.78–1.20)
TMCO1 rs12059327 C 0.71 0.97 (0.80–1.16) 0.93 1.01 (0.83–1.23) 0.28 0.85 (0.63–1.15) 0.22 1.17 (0.91–1.51)
TMCO1 rs6426940 C 0.94 1.00 (0.89–1.13) 0.98 1.00 (0.88–1.14) 0.92 1.01 (0.84–1.22) 0.31 0.91 (0.77–1.09)
TMCO1 rs7518099 C 0.048 1.27 (1.00–1.62) 0.12 1.23 (0.95–1.59) 0.05 1.39 (0.99–1.93) 0.11 1.29 (0.94–1.75)
TMCO1 rs2814471 C 0.27 1.11 (0.93–1.32) 0.80 1.03 (0.85–1.24) 0.019 1.37 (1.05–1.77) 0.76 1.04 (0.81–1.34)
CAV1/CAV2 rs8940 C 0.051 0.86 (0.74–1.00) 0.08 0.86 (0.73–1.02) 0.15 0.84 (0.66–1.06) 0.10 0.83 (0.67–1.04)
CAV1/CAV2 rs1052990 A 0.029 0.87 (0.77–0.99) 0.06 0.88 (0.77–1.00) 0.08 0.85 (0.70–1.02) 0.11 0.87 (0.73–1.03)
CAV1/CAV2 rs6466578 C 0.23 0.91 (0.78–1.06) 0.52 0.95 (0.80–1.12) 0.08 0.80 (0.62–1.03) 0.19 0.86 (0.70–1.07)
CAV1/CAV2 rs3919515 C 0.41 0.95 (0.84–1.08) 0.44 0.95 (0.83–1.09) 0.59 0.95 (0.78–1.15) 0.56 0.95 (0.79–1.13)
CAV1/CAV2 rs10227696 A 0.13 1.13 (0.97–1.31) 0.20 1.11 (0.94–1.32) 0.18 1.17 (0.93–1.49) 0.09 1.21 (0.97–1.51)
CAV1/CAV2 rs4236601 A 0.020 1.16 (1.02–1.31) 0.050 1.14 (1.00–1.31) 0.05 1.21 (1.00–1.47) 0.06 1.19 (0.99–1.42)
CAV1/CAV2 rs917664 A 0.72 1.02 (0.91–1.16) 0.75 1.02 (0.90–1.16) 0.79 1.03 (0.85–1.25) 0.98 1.00 (0.84–1.19)
CAV1/CAV2 rs3779512 A 0.43 1.05 (0.93–1.20) 0.28 1.08 (0.94–1.24) 0.90 0.99 (0.81–1.21) 0.74 1.03 (0.86–1.24)
CAV1/CAV2 rs3807986 C 0.97 1.00 (0.88–1.13) 0.93 1.01 (0.88–1.15) 0.84 0.98 (0.81–1.19) 0.015 0.80 (0.66–0.96)
CAV1/CAV2 rs3807989 C 0.97 1.00 (0.88–1.13) 0.56 0.96 (0.84–1.10) 0.28 1.12 (0.92–1.36) 0.35 0.91 (0.76–1.10)
CAV1/CAV2 rs3779514 A 0.69 1.03 (0.89–1.19) 0.41 1.07 (0.92–1.24) 0.47 0.92 (0.73–1.16) 0.84 0.98 (0.80–1.20)
CAV1/CAV2 rs3815412 A 0.51 1.04 (0.92–1.18) 0.63 1.03 (0.90–1.18) 0.54 1.06 (0.88–1.29) 0.03 0.82 (0.69–0.98)
CAV1/CAV2 rs8713 A 0.85 1.01 (0.89–1.16) 0.89 1.01 (0.87–1.17) 0.79 1.03 (0.83–1.27) 0.04 0.82 (0.68–0.99)
Chr 8q22 rs284489 C 0.69 0.98 (0.86–1.10) 0.92 0.99 (0.87–1.13) 0.44 0.93 (0.77–1.12) 0.66 1.04 (0.86–1.27)
CDKN2B-AS1 rs2069422 G 0.96 1.01 (0.82–1.23) 0.86 0.98 (0.79–1.22) 0.57 1.09 (0.80–1.49) 0.75 0.95 (0.71–1.28)
CDKN2B-AS1 rs7049105 A 0.009 0.84 (0.73–0.96) 0.013 0.83 (0.72–0.96) 0.12 0.85 (0.69–1.05) 0.75 1.03 (0.85–1.25)
CDKN2B-AS1 rs2151280 A 0.19 1.11 (0.95–1.29) 0.38 1.08 (0.91–1.27) 0.11 1.19 (0.96–1.48) 0.25 0.89 (0.73–1.08)
CDKN2B-AS1 rs7851706 C 0.26 1.11 (0.92–1.34) 0.24 1.13 (0.92–1.38) 0.66 1.07 (0.80–1.43) 0.06 0.80 (0.64–1.01)
CDKN2B-AS1 rs10120688 A 0.0020 1.21 (1.07–1.37) 0.012 1.18 (1.04–1.35) 0.004 1.32 (1.09–1.60) 0.10 0.86 (0.72–1.03)
CDKN2B-AS1 rs16905597 A 0.010 0.78 (0.64–0.94) 0.006 0.74 (0.60–0.92) 0.38 0.88 (0.66–1.18) 0.57 1.07 (0.85–1.36)
CDKN2B-AS1 rs16905599 C 0.04 0.86 (0.75–1.00) 0.04 0.85 (0.73–0.99) 0.33 0.90 (0.72–1.12) 0.28 1.12 (0.92–1.36)
CDKN2B-AS1 rs16923583 A 0.47 0.94 (0.80–1.11) 0.44 0.93 (0.78–1.11) 0.71 0.95 (0.73–1.24) 0.94 1.01 (0.81–1.25)
CDKN2B-AS1 rs1547705 A 0.43 1.07 (0.91–1.27) 0.33 1.10 (0.91–1.31) 0.97 1.01 (0.79–1.28) 0.89 1.01 (0.84–1.23)
CDKN2B-AS1 rs1537370 C 0.06 0.88 (0.77–1.00) 0.11 0.89 (0.77–1.03) 0.09 0.84 (0.68–1.03) 0.24 1.12 (0.93–1.36)
CDKN2B-AS1 rs10738607 C 0.32 0.92 (0.78–1.09) 0.16 0.88 (0.73–1.05) 0.82 1.03 (0.81–1.30) 0.95 0.99 (0.80–1.23)
CDKN2B-AS1 rs10965235 A 0.06 1.13 (1.00–1.27) 0.03 1.16 (1.01–1.32) 0.70 1.04 (0.86–1.25) 0.43 0.93 (0.79–1.11)
CDKN2B-AS1 rs4990722 G 0.55 1.05 (0.89–1.25) 0.65 1.04 (0.87–1.25) 0.41 1.12 (0.85–1.47) 0.79 0.97 (0.79–1.20)
CDKN2B-AS1 rs17761446 G 0.08 0.79 (0.60–1.03) 0.05 0.74 (0.55–1.00) 0.76 0.94 (0.63–1.41) 0.86 1.04 (0.70–1.53)
CDKN2B-AS1 rs1333049 C 0.10 0.89 (0.78–1.02) 0.07 0.87 (0.75–1.01) 0.78 0.97 (0.78–1.20) 0.68 1.05 (0.84–1.31)
CDKN2B-AS1 rs1333050 C 0.37 1.07 (0.92–1.24) 0.43 1.07 (0.91–1.26) 0.53 1.08 (0.85–1.36) 0.10 1.28 (0.95–1.73)
CDKN2B-AS1 rs10811658 A 0.04 1.17 (1.01–1.35) 0.07 1.16 (0.99–1.35) 0.08 1.21 (0.98–1.49) 0.48 1.07 (0.90–1.27)
CDKN2B-AS1 rs12347779 C 0.97 1.00 (0.78–1.27) 0.89 1.02 (0.79–1.32) 0.73 0.94 (0.65–1.35) 0.28 0.82 (0.57–1.18)
CDKN2B-AS1 rs10965245 A 0.006 0.80 (0.68–0.94) 0.0005 0.73 (0.61–0.87) 0.97 1.00 (0.78–1.27) 0.38 1.10 (0.89–1.35)
CDKN2B-AS1 rs2383208 A 0.24 0.91 (0.78–1.06) 0.42 0.94 (0.79–1.10) 0.18 0.85 (0.67–1.08) 0.47 1.09 (0.87–1.35)
CDKN2B-AS1 rs1063192 C 0.15 0.85 (0.67–1.06) 0.39 0.90 (0.70–1.15) 0.06 0.68 (0.46–1.01) 0.98 N/A
CDKN2B-AS1 rs4977756 C 0.16 0.91 (0.81–1.04) 0.41 0.95 (0.83–1.08) 0.04 0.82 (0.67–1.00) 0.44 1.07 (0.90–1.29)
CDKN2B-AS1 rs10116277 G 0.88 0.99 (0.81–1.20) 0.89 1.02 (0.82–1.26) 0.43 0.88 (0.64–1.21) 0.23 1.82 (0.68–4.85)
CDKN2B-AS1 rs4977574 A 0.48 1.05 (0.91–1.22) 0.41 1.07 (0.91–1.26) 0.99 1.00 (0.80–1.26) 0.48 1.10 (0.85–1.41)
SIX1/SIX6 rs2350890 C 0.31 1.07 (0.94–1.20) 0.42 1.06 (0.93–1.21) 0.36 1.09 (0.90–1.32) 0.65 1.04 (0.87–1.24)
SIX1/SIX6 rs4901977 A 0.99 1.00 (0.88–1.13) 0.79 0.98 (0.86–1.12) 0.67 1.04 (0.86–1.26) 0.28 1.10 (0.92–1.32)
SIX1/SIX6 rs8012339 A 0.56 0.95 (0.82–1.12) 0.31 0.92 (0.77–1.09) 0.64 1.06 (0.83–1.36) 0.69 0.96 (0.78–1.17)
SIX1/SIX6 rs1266416 C 0.50 0.96 (0.85–1.08) 0.74 0.98 (0.86–1.12) 0.24 0.90 (0.74–1.08) 0.14 1.14 (0.96–1.35)
SIX1/SIX6 rs3759688 A 0.88 1.01 (0.86–1.20) 0.97 1.00 (0.83–1.20) 0.63 1.06 (0.83–1.35) 0.86 0.98 (0.82–1.18)
SIX1/SIX6 rs11849906 G 0.43 0.91 (0.72–1.15) 0.77 1.04 (0.81–1.32) 0.006 0.53 (0.34–0.83) 0.18 1.23 (0.91–1.67)
SIX1/SIX6 rs10148202 A 0.13 0.88 (0.74–1.04) 0.18 0.88 (0.74–1.06) 0.24 0.85 (0.65–1.12) 0.72 1.04 (0.84–1.30)
SIX1/SIX6 rs7156317 A 0.73 1.02 (0.90–1.16) 0.61 1.04 (0.90–1.19) 0.87 0.98 (0.81–1.20) 0.52 1.06 (0.89–1.26)
SIX1/SIX6 rs7146104 A 0.17 1.24 (0.91–1.68) 0.23 1.22 (0.88–1.69) 0.25 1.32 (0.82–2.11) 0.70 0.93 (0.66–1.32)
SIX1/SIX6 rs10483727 C 0.67 0.96 (0.78–1.18) 0.97 0.99 (0.77–1.28) 0.66 0.92 (0.64–1.32) 0.76 1.13 (0.52–2.44)
SIX1/SIX6 rs33912345 A 0.25 0.88 (0.71–1.10) 0.91 0.99 (0.77–1.27) 0.57 0.90 (0.62–1.30) 0.93 0.96 (0.42–2.23)
P value from the logistic regression using additive model with the justification of age and sex. AA, African American. Bold indicates significance.
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the small sample size of our NPG dataset (280 cases and 999
controls), which reflects the smaller proportion of African
Americans with NPG. Cao et al.47 reported the association of
rs1063192 in this region in the Afro-Caribbean populations of
Barbados, West Indies. Consistent with our other findings, we
do not observe this association in either African Americans or
Ghanaians. The protective C allele of this SNP is rare in the
Ghanaian population (MAF ¼ 0.002 in cases versus 0 in
controls). In addition, the mean IOP of POAG cases in the
Barbados dataset was 22.5 mm Hg, significantly lower than the
26.2 mm Hg observed in our African American cases. These
facts may contribute to the lack of association with the
CDKN2B-AS1 locus in Ghanaians and African Americans.
We have also identified a significant association of
rs11849906 in the SIX1/SIX6 region in the African American
NPG subgroup (P¼0.006; OR¼0.53 6 0.34–0.83). This SNP is
monomorphic in the Caucasian and Asian populations from the
International HapMap Project (http://hapmap.ncbi.nlm.nih.
gov) and is polymorphic only in populations of African
ancestry, including African Americans and Africans in Nigeria,
Kenya. Additional studies in populations of African ancestry are
required to replicate this finding.
The lack of association with TMCO1, CAV1/CAV2, or the
chromosome 8q22 intergenic region may be secondary to the
limited sample size or perhaps due to smaller effect sizes in
populations of African ancestry compared with Caucasians.
The lack of associations with specific variants previously
identified in Caucasian populations may be explained by the
rarity of those alleles in African populations. Several associated
SNPs common in Caucasians were rare in the Ghanaians,
including rs10483727 and rs33912345 in the SIX1/SIX6
region, and rs10116277 and rs1063192 in the CDKN2B-AS1
region, potentially limiting the effect that these alleles could
have on POAG risk.
Admixture in the African Americans and genetic heteroge-
neity between the African American and Ghanaian populations
may also influence our association findings. Our meta-analysis
of these loci with the African American and Ghanaian data sets
indicates that five SNPs were nominally significant (P < 0.05)
in the meta-analysis (rs7518099 and rs2814471 in TMCO1,
rs4236601 in CAV1/CAV2, and rs10120688 and rs16905597 in
CDKN2B-AS1). Interestingly, for the SNPs in TMCO1 and
CAV1/CAV2, the ORs and risk alleles were consistent between
populations, while, for CDKN2B-AS1, the odds ratios and risk
alleles were opposite in the two populations (Table 2,
Supplementary Table S1). This suggests that some of the risk
for POAG in the African American population may be
explained by Caucasian admixture (CDKN2B-AS1), while other
POAG risk factors may be driven by African-derived risk alleles.
Mutations in myocilin and optineurin have been docu-
mented in POAG cases. Previous studies14,48–52 found that,
despite the high prevalence of POAG in the populations of
African ancestry, the mutations in these two genes play a
relatively limited role. The increased prevalence of glaucoma
in the African populations is not due to a higher prevalence of
myocilin mutations. In this study, approximately 573 African
American and 100 Ghanaian POAG cases have been screened
for myocilin mutations.49,50 Patients carrying any known
mutations were excluded from our analysis. Given the
relatively rare frequency of myocilin mutations in these
African populations, we expect that the association results
will not be affected by the lack of myocilin screening in the
remaining POAG cases. In addition, several studies have
confirmed the lack of significant association of common
variants in myocilin with POAG in Caucasian individuals.38,53
Collectively, these results suggest that other currently
unknown genetic risk factors contribute to POAG in these
African populations.
Our findings suggest that genetic associations for POAG
found in Caucasian populations appear to play a much smaller
role in populations of African ancestry, leaving a large portion
of genetic architecture of African POAG to be determined.
This is not surprising, as Africa in general, and Sub-Saharan
Africa in particular, contains the anthropologically oldest and
most heterogeneous populations on Earth who have experi-
enced environmental conditions that have historically con-
tributed unique selection pressures. In the long term, multiple
GWASs of POAG in populations of African descent will be
required to not only validate the known glaucoma loci, but
also to identify novel variants and loci in specific populations
of African ancestry that contribute to POAG pathogenesis and
related blindness.
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